APA (7th ed.) Citation

Thepot, S., Boehrer, S., Seegers, V., Prebet, T., Beyne-Rauzy, O., Wattel, E., . . . Adès, L. (2014). A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leukemia Research, 38(12), 1430. https://doi.org/10.1016/j.leukres.2014.09.014

Chicago Style (17th ed.) Citation

Thepot, Sylvain, et al. "A Phase I/II Trial of Erlotinib in Higher Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia After Azacitidine Failure." Leukemia Research 38, no. 12 (2014): 1430. https://doi.org/10.1016/j.leukres.2014.09.014.

MLA (9th ed.) Citation

Thepot, Sylvain, et al. "A Phase I/II Trial of Erlotinib in Higher Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia After Azacitidine Failure." Leukemia Research, vol. 38, no. 12, 2014, p. 1430, https://doi.org/10.1016/j.leukres.2014.09.014.